Navigation Links
Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer

Summary: Exiqon Today Announced the Appointment of Cynthia K. French, Ph.D. as Chief Scientific Officer and Erik Holmlin, Ph.D. as Chief Commercial


VEDBAEK, Denmark, June 30 /PRNewswire-FirstCall/ -- Cynthia K. French joins Exiqon from Affymetrix where she served as Vice President, Clinical Services Laboratory and was responsible for building and operating the CLIA laboratory. Prior to Affymetrix, Cynthia served as Vice President, Chief Scientific Officer at Speciality Laboratories and before then she held a number of senior positions at Quest Diagnostics Inc., Pluvita, Bio-Rad Laboratories, Diagnostic Products Corporation and Du Pont. Cynthia was the co-founder of Plutiva and she was responsible for the merger of the company with Diogenics. Cynthia brings extensive experience in managing product development, clinical trials, ISO and CLIA operations to Exiqon.

Cynthia received her Ph.D. and MBA from the University of California and she was a postdoctoral fellow at MIT and Harvard University. As Chief Scientific Officer, Cynthia will be responsible for the development of Exiqon's research products and our new diagnostic products including the CLIA laboratory.

Erik Holmlin joins Exiqon from BD Diagnostics, GeneOhm, where he held a number of executive positions within marketing, technology and strategy. Erik was one of the founders of GeneOhm, which he formed in 2001 and sold to BD Diagnostics for USD 255 million in 2006.

Erik earned his Ph.D. degree in chemistry from the California Institute of Technology in Pasadena and held a postdoctoral position at Harvard University. Erik also holds an MBA degree from UC Berkeley. In his new position as Exiqon's Chief Commercial Officer, Erik will be responsible for managing sales & marketing of all products and services related to both research products and diagnostics.

Both Cynthia and Erik will be based at Oncotech Inc. in Tustin, California, a wholly owned subsidiary of Exiqon A/S.

Lars Kongsbak, President and CEO says: "Cynthia and Erik bring broad management and operational experience in the life science and diagnostic marketplace to Exiqon. We are excited to have Cynthia and Erik join our team and strengthen our focus on the US market."

About Exiqon

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA(TM) technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA(TM) or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics. Exiqon has facilities in Denmark, Boston (MA) and Tustin (CA).


Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.

This announcement is not an offer of securities for sale in Exiqon. The shares in Exiqon have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any State securities laws and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws and applicable State securities laws.

For more information, please contact:

Exiqon A/S,

Lars Kongsbak, President and CEO, tel. +45-40-90-21-01,

Hans Henrik Chrois Christensen, CFO, tel. +45-40-90-2131.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon: Major Shareholder Announcement
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the “hairy ... a depiction of a system of linkages and connections so complex and dense ... of computer science at Worcester Polytechnic Institute (WPI) and director of the university’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... publication of a United States multicenter, prospective clinical study that demonstrates the ... diagnostic test capable of identifying clinically significant acute bacterial and viral respiratory ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):